ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2441

Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis

Alan M. Rosenberg1, Walter Maksymowych2, Yuan Gui3 and Anthony Marotta3, 1Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Augurex Life Sciences Corp., Vancouver, BC, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: diagnosis, juvenile idiopathic arthritis-enthesitis (ERA) and polyarthritis, Rheumatoid Factor

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 10, 2015

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters (ACR): Imaging and Novel Clinical Interventions

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile
Idiopathic Arthritis (JIA) is a collective term used to denote clinically
discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis,
Polyarthritis, Psoriatic arthritis, Systemic arthritis and unclassified
arthritis. Polyarthritis is further categorized according to rheumatoid factor
(RF) status. The International League of Associations for Rheumatology (ILAR)
has devised classification criteria of JIA with specific exclusion criteria and
its diagnosis is reliant upon clinical symptoms. While laboratory tests like
CBC, CRP, ESR, RF, ANA, and anti-CCP add prognostic value, they have limited
utility for diagnosis. Thus, markers that can assist in sub-typing JIA at
presentation are imperative as this can influence patient management strategy.
14-3-3η is a joint derived, rheumatoid arthritis (RA) specific marker that
informs radiographic damage. The purpose of this study was to examine the
expression of 14-3-3η in the sub-types of JIA, and to assess whether a relationship
existed between 14-3-3η and RF+ polyarthritis.

Methods:
14-3-3η serum levels were measured in 60 JIA patients as shown in Table 1.
One-way ANOVA analysis was used to determine if group differences existed.
14-3-3η positivity was defined using the adult RA diagnostic cut-off of
≥0.19 ng/ml. The Fisher’s Exact test was employed to assess the
relationship between RF and 14-3-3η positivity in polyarthritis patients.

Results:
ANOVA analysis revealed differences in 14-3-3η serum levels between the
groups. Patients with RF positive polyarticular disease had significantly
higher serum 14-3-3η levels than the other groups. 14-3-3η positivity
analysis revealed that 30% of the oligoarthritis, 53% of RF negative
polyarticular, 50% of psoriatic and 57% of patients with systemic arthritis
were positive for 14-3-3η. Although there were only four patients in the
enthesitis group, none of them were 14-3-3η positive. Fisher’s Exact
testing returned no significant association between RF and 14-3-3η
positive status (p-value = 0.35) indicating that the two markers may uniquely
inform patient profiles within subtypes of JIA, especially since 53% of RF
negative polyarticular JIA patients had positive 14-3-3η tests. 

 

Enthesitis

Oligo

Poly, RF-

Poly, RF+

Psoriatic

Systemic

# of Pts

4

21

19

7

2

7

Median

(QR)

0.06

(0.02-0.09)

0.10

(0.02-0.23)

0.19

(0.02-0.33)

1.83

(0.09-10.59)

0.20

(0.01-0.38)

0.20

(0.01-1.54)

Mean (SD)

0.06 (0.04)

0.23 (0.35)

0.29 (0.38)

4.69 (6.51)

0.20 (0.26)

0.55 (0.69)

% Positivity (n)

0% (0)

30% (7)

53% (10)

71% (5)

50% (1)

57% (4)

ANOVA

p=0.0008

 

Conclusion: 14-3-3η is a joint-derived mechanistic marker that up-regulates
factors that are involved in joint damage pathogenesis. While RF+ polyarthritis
patients had higher 14-3-3η levels, in JIA, 14-3-3η expression has no
significant association with RF positivity and may provide insights into
biochemical processes that uniquely inform JIA sub-typing. 


Disclosure: A. M. Rosenberg, None; W. Maksymowych, Augurex Life Sciences, 5; Y. Gui, Augurex Life Sciences Corp, 3; A. Marotta, Augurex Life Sciences Corp, 3.

To cite this abstract in AMA style:

Rosenberg AM, Maksymowych W, Gui Y, Marotta A. Serum 14-3-3η Is Present in JIA and Is Not Associated with RF+ Polyarthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/serum-14-3-3-is-present-in-jia-and-is-not-associated-with-rf-polyarthritis/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-14-3-3-is-present-in-jia-and-is-not-associated-with-rf-polyarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.